首页 | 本学科首页   官方微博 | 高级检索  
     

血清CK-MB/CK大于45.9%在肿瘤筛查中的应用
引用本文:李孝才,姜立敬. 血清CK-MB/CK大于45.9%在肿瘤筛查中的应用[J]. 医学检验与临床, 2014, 0(3): 15-16
作者姓名:李孝才  姜立敬
作者单位:山东省聊城市光明医院检验科,山东聊城252000
摘    要:目的:评价血清肌酸激酶同工酶(CK-MB)活性与肌酸激酶(CK)活性的比值在健康体检人员中进行恶性肿瘤筛查的价值。方法:回顾性研究。收集2009年8月至2013年9月间的住院患者,经组织病理学检查确诊为恶性肿瘤的患者120例,健康对照组120例为来我院健康体检者,排除恶性肿瘤及任何心源性及其它疾病。用BECKMAN COULTER AU680生化系统进行血清肌酸激酶同工酶和肌酸激酶活性的检测,计算二者的比值,并采用t检验进行统计学分析。结果:健康对照组120例,CK-MB/CK平均值为25.2%,肿瘤组CK-MB/CK的平均值为45.9%,经统计学分析,二者有显著区别。结论:健康查体人员若CK-MB/CK升高,应该做进一步的检查,以便排除是否有恶性肿瘤的发生。

关 键 词:恶性肿瘤  肌酸激酶  同工酶  肌酸激酶  CK-MB/CK

The application of serum CK-MB/CK exceed 45.9% in tumor screening
LI Xiao-cai,JIANG Li-jing. The application of serum CK-MB/CK exceed 45.9% in tumor screening[J]. Medical Laboratory Science and, 2014, 0(3): 15-16
Authors:LI Xiao-cai  JIANG Li-jing
Affiliation:(clinical Laboratory of Liaocheng Guangming Hospital, Liaocheng Shandong 252000)
Abstract:Objective:Evaluation of serum creatine kinase isoenzyme (CK - MB) activity and the ratio of creatine kinase (CK) activity in the healthy physical examination personnel in the value of screening for malignant tumor.Methods:Collected in August 2009 to September 2013 hospitalized patients.Diagnosis of malignant tumor by histopathological examination, 120 cases of patients. Healthy control group 120 cases for our health, Exclude malignant tumor and any cardiac and other diseases.Detection of creatine kinase isozyme and the activity of creatine kinase With BECKMAN CO ULTER AU680,Calculate the ratio of the two, And USES the T test for statistical analysis.Results:Healthy control group (n = 120), CK - MB/CK average of 25.2%, CK - MB/CK tumor group average of 45.9%, After statistics analysis, Both have significant differences.Conclusions:If CK - MB/CK elevated in Healthy physical examination personnel, Should do further check, In order to eliminate the occurrence of malignant tumor.
Keywords:Malignant tumor  Creatine kinase isoenzyme  Creatine kinase  CK-MB/CK
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号